Formulations and Development of Nanoemulsion based Gel Loaded and Piperine-Loaded with Phytoconstituents for the treatment of Urinary Tract Infection
Keywords:
Nanoemulsion, Gel Loaded, Piperine-Loaded, Urinary Tract InfectionAbstract
The intravaginal delivery of a nanoemulsion gel comprising polyphenon 60 (P60) and cranberry (CRB) has been developed for the treatment of urinary tract infections. Utilizing an ultra-sonication technique, cranberry and polyphenon 60 were combined into a single nanoemulsion gel (NBG). Because of its low solubility in water, the alkaloid piperine has limited therapeutic effectiveness. Using oleic acid (oil), Cremophore EL (surfactant), and Tween 80 (co-surfactant), piperine nanoemulsions were generated in this work by the use of high-energy ultrasonication. Researchers used TEM, release, permeation, antibacterial, and cell viability tests to determine the best nanoemulsion (N2), which they predicated on the smallest possible droplet size and the highest possible encapsulation effectiveness. The droplet size of the finalized NE was 58±1 nm. In addition, radiolabeled P60+CRB NBG demonstrated a markedly increased absorption of radio labelled actives by the kidney (3.20±0.16) and urine bladder (3.64±0.29) in biodistribution tests conducted intravaginally. According to the results, piperine nanoemulsions might be a better nanodrug delivery technology than the ones now in use.
References
Andrea R. Thurman, Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial, E-Clinical Medicine 36 (2021) 100893
Robinson, Jennifer A et al. “Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).” Journal of acquired immune deficiency syndromes (1999) vol. 77,2 (2018): 175-182. doi:10.1097/QAI.0000000000001587
Gilbert Lazarus, Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials, Front. Pharmacol., 07 July 2021
Guolan Wu, Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women, Front. Pharmacol., 20 April 2017
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, et al. (2018) Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med 15(11): e1002690. https://doi.org/10.1371/journal.pmed.1002690
A.Aronsson, Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol, Human Reproduction Vol.22, No.7 pp. 1912–1918, 2007
Govil, S., Katz, D.F. Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood. Sci Rep 9, 82 (2019). https://doi.org/10.1038/s41598-018-36004-z
Denison, Hayley J et al. “Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).” The Cochrane database of systematic reviews vol. 8,8 CD002845. 24 Aug. 2020, doi: 10.1002/14651858.CD002845.pub3
Srinivasan U, Misra D, Marazita ML, Foxman B. Vaginal and oral microbes, host genotype and preterm birth. Med Hypotheses. 2009;73(6):963-975. doi: 10.1016/j.mehy.2009.06.017
Heather L, Vaginitis: Diagnosis and Treatment, American Family Physician www.aafp.org/afp Volume 97, Number 5, March 1, 2018
This work is licensed under a 